BRCA2 and Patent ductus arteriosus: More recently, Kausar et al. demonstrated that MK-1775 through WEE1 inhibition sensitized BRCA2 wild-type (MIA PaCa2 and PANC-1) cells, but not the DDR-deficient (BRCA2 mutant) PDA cells to gemcitabine-radiation39.